FIA
IMNM icon

FNY Investment Advisers’s Immunome IMNM Stock Holding History

FNY Investment Advisers’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-337
Closed -$2K – 666
2023
Q2 		$2K Buy
+337
New +$1.84K ﹤0.01% 443

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

FNY Investment Advisers's IMNM Position: Q1 2026 in Review

FNY Investment Advisers sold out of Immunome (IMNM) in Q1 2026, closing a stake of 50 shares — an estimated $1K sold.

FNY Investment Advisers first reported a position in IMNM in Q2 2023 and held it in 3 quarters. The position peaked at $58K in Q2 2024. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • FNY Investment Advisers reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 50 Immunome shares in Q1 2026, an estimated $1K.
  • FNY Investment Advisers first reported a position in Immunome in Q2 2023 and held it in 3 quarters.
  • FNY Investment Advisers's Immunome position peaked at $58K in Q2 2024.
  • 201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.